SCHEMBL581969

SCHEMBL581969

O=c1cc([C@H]2CCN[C@H](c3ccc(F)c(F)c3)C2)o[nH]1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLG P00747 13/20 0.56
GABRA1 P14867 1/20 0.49
GABRG2 P18507 1/20 0.49
GABRB3 P28472 1/20 0.49
KDM1A O60341 1/20 0.34
MAOB P27338 1/20 0.34
CHRNB2 P17787 1/20 0.31
ADRA2C P18825 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA7 P36544 1/20 0.31
CHRNA4 P43681 1/20 0.31
TMEM97 Q5BJF2 1/20 0.31
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL581971 1.00 PLG (0.56) PLGGABRA1GABRG2GABRB3KDM1A
SCHEMBL582077 1.00 PLG (0.56) PLGGABRA1GABRG2GABRB3KDM1A
SCHEMBL581970 1.00 PLG (0.56) PLGGABRA1GABRG2GABRB3KDM1A
Acetic Acid SCHEMBL27965793 0.93 PLG (0.53) PLGGABRA1GABRG2GABRB3KDM1A
Acetic Acid SCHEMBL28812566 0.93 PLG (0.53) PLGGABRA1GABRG2GABRB3KDM1A
SCHEMBL581922 0.90 PLG (0.53) PLGGABRA1GABRG2GABRB3
SCHEMBL581774 0.90 PLG (0.53) PLGGABRA1GABRG2GABRB3
SCHEMBL581921 0.90 PLG (0.53) PLGGABRA1GABRG2GABRB3
SCHEMBL581920 0.90 PLG (0.53) PLGGABRA1GABRG2GABRB3
SCHEMBL582071 0.88 PLG (0.65) PLGGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 US claimed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US claimed
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 US disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 EP disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 PLG 4861/4885GABRA1 237/4885GABRG2 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.